KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Debt: 2020-2024

Historic Non-Current Debt for Regeneron Pharmaceuticals (REGN) over the last 5 years, with Dec 2024 value amounting to $2.0 billion.

  • Regeneron Pharmaceuticals' Non-Current Debt rose 0.10% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 0.10%. This contributed to the annual value of $2.0 billion for FY2024, which is 0.08% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Non-Current Debt stood at $2.0 billion for FY2024, which was up 0.08% from $2.0 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' Non-Current Debt's 5-year high stood at $2.0 billion during FY2024, with a 5-year trough of $2.0 billion in FY2020.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Non-Current Debt value was $2.0 billion (recorded in 2023), while the average stood at $2.0 billion.
  • Data for Regeneron Pharmaceuticals' Non-Current Debt shows a peak YoY increased of 0.08% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Non-Current Debt stood at $2.0 billion in 2020, then rose by 0.08% to $2.0 billion in 2021, then climbed by 0.07% to $2.0 billion in 2022, then climbed by 0.08% to $2.0 billion in 2023, then grew by 0.08% to $2.0 billion in 2024.